CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for WuXi PharmaTech (Cayman) Inc. (ADR) is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

WuXi PharmaTech (Cayman) Inc. (ADR)
288 Fute Zhong Road
Waigaoqiao Free Trade Zone
Phone: +86 2150461111p:+86 2150461111 Shanghai, SHA  200131  China Fax: +86 2150461000f:+86 2150461000

On 12/10/2015, WuXi PharmaTech (Cayman) Inc. announced the completion of its merger with WuXi Merger Limited, a wholly-owned subsidiary of New WuXi Life Science Limited, pursuant to the previously announced Agreement and Plan of Merger. As a result of the Merger, New Wuxi Life Science Limited acquired WuXi PharmaTech (Cayman) Inc., the shares of WuXi PharmaTech (Cayman) Inc. were delisted, and WuXi PharmaTech (Cayman) Inc. became a private company.

Business Summary
WuXi PharmaTech (Cayman) Inc. is a pharmaceutical, biotechnology and medical device research and development (R&D) services company, with operations in China and the United States. The Company provides a portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process to its customers. It conducts its operations in two segments: Laboratory services and Manufacturing services. The Company offers Laboratory services for pharmaceutical, biotechnology and medical device companies. It offers Manufacturing services, which include the development of manufacturing processes and the production of advanced intermediates and active pharmaceutical ingredients (APIs) for use by pharmaceutical companies in preclinical and clinical trials of small-molecule products and in commercial products, as well as the production of biologic products.
(Source: 20-F)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/201512/31/2014YesYes--Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board, Chief Executive Officer GeLi 48 1/1/2004 1/1/2000
Chief Financial Officer, Chief Investment Officer EdwardHu 52 4/15/2014 8/13/2007
Chief Operating Officer, Executive Vice President SteveYang 46 4/15/2014 4/15/2014
12 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
HD Biosciences Co., Ltd. 590 Ruiqing Road Shanghai China
NextCODE Health 101 Main St. Cambridge MA United States
WuXi AppTec Inc. 6 Cedarbrook Dr. Cranbury NJ USA
4 additional Subsidiary records available in full report.

Business Names
Business Name
Abgent Biotechnology (Suzhou) Co., Ltd.
Abgent Europe Limited
Abgent, Inc.
49 additional Business Names available in full report.

General Information
Number of Employees: 9,082 (As of 4/3/2015)
Outstanding Shares: 568,019,232 (As of 9/30/2015)
Shareholders: 12
Stock Exchange: NYSE
Fax Number: +86 2150461000


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023